Nexvet Biopharma Builds Drug-Development Fund
April 17, 2014
Investors poured $31.5 million into the coffers of veterinary drug developer Nexvet Biopharma, an Australian company that is researching medications that could be used to treat feline and canine pain and canine atopic dermatitis. The closing of the Series B, or second, round of financing was announced Wednesday. The proceeds are intended to assist Nexvet's… Continue reading...